Axoft is a Cambridge, Massachusetts neurotechnology company building implantable brain-computer interfaces (iBCIs) out of Fleuron, a proprietary material it claims is up to 10,000x softer than the polyimide used in conventional brain implants. By making electronics roughly as soft as brain tissue, Axoft aims to keep thousands of sensors in stable contact with single neurons for years instead of months - reducing scarring and signal loss - to diagnose and eventually treat disorders of consciousness, paralysis, and other neurological conditions. A Harvard spinout founded in 2021, it raised an oversubscribed $55M Series A in April 2026 and has run first-in-human studies in 11+ patients worldwide.
Paul Le Floch is the co-founder and CEO of Axoft, a Cambridge neurotechnology company building brain implants out of a material so soft it behaves like brain tissue. A Harvard-trained materials scientist and Forbes 30 Under 30 honoree, he bet that the way to read the brain better was not to borrow chips from the semiconductor industry but to invent a new material from scratch. The result, Fleuron, is up to thousands of times softer than conventional probes yet can carry over 1,000 sensors. Axoft has now implanted its device in 11 patients and raised a $55M Series A to push toward FDA trials.